COMP <GO>
DNA vs UNH // GROSS PROFIT MARGIN
Ginkgo Bioworks Holdings Inc. (Class A) (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: DNA 0
— UNH 9
■ METRIC PARITY
LAST: $11.21 (-12.01%) • MKT CAP: $819.7M
gross-margins
—
LAST: $406.97 (-0.96%) • MKT CAP: $368.83B
gross-margins
88.57%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DNA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 11.47% | -46.47 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -21.80% | 6.48% | -28.28 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -0.20% | 3.14% | -3.34 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -25.10% | 6.46% | -31.56 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.4 | 59.2 | -0.80 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $819.7M | $368.83B | -$368.01B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DNA REV | UNH REV | DNA GROSS % | UNH GROSS % | DNA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $170.2M | $447.57B | — | 88.7% | -$178.7M | $16.07B |
| FY 2024 | $227.0M | $400.28B | — | 88.3% | -$382.1M | $20.70B |
| FY 2023 | $251.5M | $371.62B | — | 89.6% | -$295.5M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNA // BETA —
UNH // BETA 0.33